About AC Immune SA (ACIU):

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.